{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"7.9","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"From initiation of treatment with nivolumab until the time of disease progression, time measured in months. Kaplan-Meier analysis performed to estimate the median progression-free survival with a 95% confidence interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"This outcome measure is assessed from patients enrolled onto Part A of this study.","id":"OG000","title":"Part A: Nivolumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initiation of treatment with nivolumab until the time of disease progression, assessed up to 2 years","title":"Progression-free Survival (Part A)","type":"SECONDARY","unitOfMeasure":"months"}